PLPPR5

Across TCGA pan-cancer cohorts, PLPPR5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLPPR5 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PLPPR5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLPPR5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, TGCT, and READ are the cancer types where PLPPR5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
TGCT	DFS	Median	All	0.082	0.837	<.001	6	view →
READ	OS	Median	All	0.281	0.822	.023	6	view →
COAD	DFS	Median	II,III,IV	0.178	0.690	.006	6	view →
PRAD	DFS	Median	All	0.187	0.777	.001	4	view →
UCEC	DFS	Median	II,III,IV	0.915	0.439	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLPPR5–DLBC (OS)

Open the DLBC breakdown →